Cargando…
Romosozumab and antiresorptive treatment: the importance of treatment sequence
SUMMARY: To evaluate whether treatment sequence affects romosozumab response, this analysis reviewed studies where romosozumab was administered before or following an antiresorptive (alendronate or denosumab). Initial treatment with romosozumab followed by an antiresorptive resulted in larger increa...
Autores principales: | Cosman, Felicia, Kendler, David L., Langdahl, Bente L., Leder, Benjamin Z., Lewiecki, E. Michael, Miyauchi, Akimitsu, Rojeski, Maria, McDermott, Michele, Oates, Mary K., Milmont, Cassandra E., Libanati, Cesar, Ferrari, Serge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106644/ https://www.ncbi.nlm.nih.gov/pubmed/35165774 http://dx.doi.org/10.1007/s00198-021-06174-0 |
Ejemplares similares
-
T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020) -
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021) -
OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020) -
The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019) -
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)